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Background: The +294T/C polymorphism in the peroxisome proliferator-activated receptor delta (PPARD) gene is
associated with hyperlipidemia in several younger populations, but results are still inconsistence across ethnic
groups and its possible impact on the lipid profiles of long-lived individuals remains unexploited. Here, we aimed
to evaluate the possible correlation between PPARD +294T/C and serum lipid levels in a long-lived population in
Bama, a region known for longevity situated in Guangxi, China.
Methods: Genotyping of PPARD +294T/C polymorphism was conducted in 505 long-lived inhabitants (aged 90
and above, long-lived group, LG) and 468 healthy controls (aged 60–75, non-long-lived group, non-LG) recruited
from Bama area.
Results: No difference in allelic and genotypic frequencies was found between the two groups (P > 0.05). However,
C-allele and C-genotype (TC and CC) were significantly more frequent in the females of non-LG than were LG after
sex stratification. CC carriers exhibited higher LDL-C level in LG (P < 0.05) but lower TC, TG and LDL-C in non-LG
(P < 0.05 for each) than TT carriers; C allele carriers (TC/CC) in LG exhibited higher TC, TG, and LDL-C levels as compared
with the same genotype and the same lipid parameter in non-LG (P < 0.05 for each). LDL-C in LG was correlated with
genotypes while TC, TG, and LDL-C in non-LG were correlated with genotypes (P < 0.05-0.001).
Conclusion: Our results suggest that there were different impact patterns of PPARD +294T/C polymorphism on
lipid profiles between long-lived cohort and average population in Bama area and this may be one of the genetic
bases of its longevity.
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The peroxisome proliferator-activated receptors (PPARs)
belong to a superfamily of nuclear receptors. Three sub-
types of PPARs, α, γ and δ, have been identified to date,
with distinct roles in lipid and glucose metabolism. They
are encoded by separate genes and characterized by dis-
tinct tissue-specific distribution patterns. PPARα and γ
are primarily produced in the liver and adipocytes
respectively and regulate fatty acid oxidation and adi-
pogenesis accordingly, whereas PPARδ is ubiquitously
expressed, with higher levels found in adipose tissue and
skeletal muscle which might involve in the regulation of
the β-oxidation of fatty acid [1-4]. In this context, dis-
turbance in levels or activity of PPARs may elicit meta-
bolic traits. In recent years, a number of efforts have
thus been directed to the putative link between PPARs
and age-related phenotypes such as metabolic syndrome,
coronary heart disease (CHD) and Alzheimer’s disease
(AD) [5,6], some of which have been well established
both in animal and human models. Of these, PPARδ has
been of burgeoning interest and proposed as a key
player in the regulation of energy metabolism due to its
ability to enhance fatty acid catabolism, energy uncoup-
ling and insulin sensitivity in multiple tissues [7].
The PPARD gene that encodes human PPARδ is mapped
to 6p21.2-p21.1 with 11 exons encompassing 35 Kbp [8].
Recent works have highlighted the potential roles for
functional variants in PPARD gene in modulating its
mRNA and protein levels which, in turn, affect genes
regulated by PPARD [9-14]. Nine most common poly-
morphisms had been identified in PPARD: four in the
intron, one in the 5′ untranslated region, and four in
the 3′ untranslated region: c.-13598C > T, c.-13454G >
T, c. + 294 T > C, c.285 + 700 T > C, c.285 + 793C > T,
c.2022 + 12G > A, c.2022 + 351 T > C, c.2629 T > C, and
c.2806C > G [9]. One of them, +294 T > C (rs2016520,
also named -87 T > C or +15C > T), a T/C transition in
nucleotide 15 of exon 4 located 87 base pairs before the
start codon, is mostly studied in view of its critical role
in lipid modulation [7,12]. The rare C allele versus the
common T allele was shown to be associated with higher
transcriptional activity and to influence binding of
Sp-1 transcription factor [15]. Furthermore, subjects
homogenous for C allele showed higher low density
lipoprotein (LDL-C) level and a propensity towards a
higher risk of CHD than T/T homozygotes [12,13,15-18],
albeit conflicting results still exist in diverse populations
[17-19]. Very recently, PPARδ was indicated to have
anti-senescence activity in cultured human coronary
artery endothelial cells [14]. Together, these results
address that PPARD +294T/C polymorphism may play
pivotal roles in the development of metabolic perturba-
tions and subsequent aged-related pathologies, impact-
ing consequently mortality and longevity in a givenpopulation. However, it is worth noting that the associ-
ation studies between PPARD +294T/C polymorphism
and serum lipid profiles were primarily undertaken in
younger cohorts of European ancestry, data from popu-
lation with exceptional longevity, particularly from
China’s minorities, are evidently scarce. Bama long-lived
individuals, a unique cohort reside along the midstream
of Hongshuihe River in Guangxi Province, P. R. China,
has emerged as an optimal cohort for human aging/
longevity study in view of its low genetic background
over the past decades [20]. Herein, we set out to test the
hypothesis that the PPARD +294T/C polymorphism is
associated with plasma lipid profile and longevity in
Bama nonagenarians/centenarians of Zhuang ethnic origin.
Materials and methods
Study population
We studied 505 nonagenarians/centenarians (127 males
and 378 females, age 93.29 ± 2.93 and range 90–104 years,
referred to hereafter as the long-lived group or LG)
who were recruited from Bama area (Bama, Fengshan,
Donglan, and Du’an County) along the midstream of
Hongshuihe River Basin, Guangxi Zhuang Autonomous
Region, the People’s Republic of China. A total of 468
volunteers (212 males and 256 females, age 68.28 ± 4.66
and range 60–75 years) without a familial history of
exceptional longevity (no past or current nonagenarian/
centenarian in the first, second and third degree rela-
tives) were randomly recruited as controls (non-long-
lived group, non-LG) from the same geographic region.
All subjects under investigation were unrelated and
belong to Zhuang ethnic group, the China’s largest
minority mainly living in Guangxi. All subjects were
essentially healthy and had no evidence of any chronic
illness, including hepatic, renal, or thyroid. The partici-
pants with a history of myocardial infarction, stroke,
diabetes were also excluded. The current study was
approved by the Ethics Committee of Guangxi Medical
University. Informed consent was obtained from all
subjects or their proxies after receiving full explanation
of the study.
Epidemiological survey
Socio-demographic information was obtained using a
standardized questionnaire. Anthropometric variables
including height, weight and waist were measured in all
groups. Body mass index (BMI) was calculated as weight
(kg)/height2 (m). Sitting blood pressure was measured 3
times, using a standard mercury sphygmomanometer
with the subject resting for at least 5 minutes before
measurement, and the average of the 3 measurements
was used for the level of blood pressure. Systolic blood
pressure was determined by the first Korotkoff sound;
and diastolic, by the fifth Korotkoff sound. Hypertension
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or diastolic blood pressure > 90 mmHg. Normal weight,
overweight, and obesity were defined as a BMI < 24, 24
to 28, and > 28 kg/m2, respectively [21].
Biochemical measurements
A venous blood sample of 8 mL was drawn from each
subject after an overnight fast, 4 mL of which was for
serum separation and subsequent lipid determination
while the remaining was transferred to an anticoagu-
lant tube (4.80 g/L citric acid, 14.70 g/L glucose, and
13.20 g/L trisodium citrate) for DNA extraction. Total
cholesterol (TC), triglycerides (TG), LDL-C and high
density lipoprotein cholesterol (HDL-C) concentra-
tions were measured by standard enzymatic methods
using commercially available kits (Daiichi Pure Chemi-
cals Co, Ltd., Tokyo, Japan) on a biochemical analyzer
(Type 7170A; Hitachi Ltd, Tokyo, Japan) at the Clinical
Science Experimental Center of the First Affiliated
Hospital, Guangxi Medical University. The normal
ranges of serum TC, TG, HDL-C, and LDL-C levels in the
Center were 3.10-5.17, 0.56-1.70, 0.91-1.81, and 1.70-
3.20 mmol/L, respectively. The individuals with TC >
5.17 mmol/L and/or TG > 1.70 mmol/L were defined as
hyperlipidemic or dyslipidemia [22].
Genotyping
Genomic DNA was extracted from white blood cells
using standard methods [23]. Genotyping for the
PPARD +294 T > C polymorphism was performed
using polymerase chain reaction (PCR)-based restrictionFigure 1 Genotype results of PPARD +294T/C polymorphism. (A) Lane
(269 bp); lane 4, 5, CC genotype (167- and 102-bp); and lanes 6, 7, TC geno
PPARD +294T/C SNP. CC, TT, and TC genotypes.fragment length polymorphism (RFLP) as described by
Wang et al. [24]. Briefly, a 269 bp fragment in the 5′-un-
translated region of exon 4 of the PPARD gene was ampli-
fied by using primers 5′-CATGGTATAGCACTGCAG
GAA-3′ (forward) and 5′-CTTCCTCCTGTGGCTGC
TC-3′ (reverse) (Sangon Biotech, China). PCR was
performed in a volume of 20 μL containing 200 ng of
genomic DNA, 10 μL of Taq MasterMix (Beijing CoWin
Bioscience, China), 6.25 μM (1.0 μL) of each primer,
7 μL ddH2O and 1 U of DNA polymerase [Takara Bio-
technology, DaLian, China]. PCR conditions were: 95°C
for an initial 5 min, followed by 35 cycles of 95°C
45 sec, 62°C 45 sec, and 72°C 45 sec, with a final 5 min
extension at 72°C. The PCR products (10 μL) were
digested with Bsl I (5 U) restriction endonuclease (New
England Biolabs, Beijing, China) at 55°C overnight,
and the fragments were separated on a 3% agarose
gel containing ethidium-bromide and visualized with
UV light. Band(s) at 269 bp only, at 269, 167, and
102 bp, and at 167, 102 bp indicate(s) TT, TC, and
CC genotype, respectively (Figure 1A). To assess
genotyping reliability, six samples (two for each geno-
type) were confirmed by direct sequencing in Sangon
Biological Engineering Technology & Services Co.,
Ltd., China (Figure 1B). Laboratory technicians who
performed genotyping were masked to clinical and
biochemical data.
Statistical analysis
Levels of the quantitative variables are presented as
mean ± SD. Allelic and genotypic frequencies wereM, 100 bp marker ladder; lanes 1, PCR product; lane 2, 3, TT genotype
type (269-, 167- and 102-bp). (B) Partial nucleotide sequences of
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eral characteristics between study groups and test for
Hardy-Weinberg equilibrium were performed with the
Pearson chi-square test. The statistical evaluation for
the categorical variables was based on the calculation
of the Student t-test. The association between the
+294T/C polymorphism and lipid variables was tested
by analysis of covariance (ANCOVA). Multiple logistic
analyses with stepwise modeling were used to evaluate
the association of serum lipid levels with genotypes
(TT = 1, TC = 2, CC = 3) and several environment
factors. All reported P values are from two-sided tests.
A P-value < 0.05 was considered statistically signifi-
cant. All analyses were performed using SPSS 13.0
(SPSS Inc, Chicago, IL).
Results
General characteristics and serum lipid levels
The basic demographic, clinical, and biochemical char-
acteristics of participants of LG and non-LG are shown
in Table 1. BMI was significantly lower in the LG as
compared to non-LG group (P = 0.001). The levels of
blood pressure, hypertension rate and unfavorable
lipoprotein (TC, TG and LDL-C) were significantly
higher (P < 0.01 for all) while the level of favorable
lipoprotein (HDL-C) was slightly lower but did not
reach statistical significance in LG than in controls.
Despite the higher lipoprotein levels in LG, however,Table 1 Comparison of clinical characteristics and serum
lipid profiles between LG and non-LG
Parameter LG (n = 505) Non-LG (n = 468) t (χ2) P
N (male/female) 127/378 212/256 43.445 0.000
Age (years) 93.29 ± 2.93 68.28 ± 4.66 41.967 0.000
Chest (cm) 79.38 ± 7.28 81.30 ± 7.21 −4.057 0.000
Waist (cm) 77.02 ± 9.52 75.73 ± 9.26 2.101 0.036
Hip (cm) 84.25 ± 6.62 87.06 ± 6.38 −6.588 0.927
BMI (kg/m2) 20.22 ± 3.43 20.94 ± 3.17 −3.401 0.001
SBP (mmHg) 166.23 ± 28.14 149.45 ± 25.31 9.792 0.000
DBP (mmHg) 89.21 ± 13.65 84.76 ± 12.28 5.342 0.000
TC (mM) 5.08 ± 1.01 4.91 ± 0.94 2.656 0.008
TG (mM) 0.97(0.49) 0.93(0.47) 1.878 0.006
HDL-C (mM) 1.58 ± 0.38 1.62 ± 0.37 −1.550 0.122
LDL-C (mM) 3.00 ± 0.86 2.82 ± 0.80 3.491 0.001
Dyslipidemia n(%) 240(47.52) 204(43.59) 1.516 0.218
Hypertension n(%) 425(84.16) 290(61.97) 61.396 0.000
LG, long-lived group; non-LG, non-long-lived group; BMI: body mass index;
SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol;
TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol. The values of triglyceride were presented as median
(interquartile range) due to non-Gaussian distribution. The difference between
the two groups was determined by the Wilcoxon-Mann–Whitney test.the prevalence of dyslipidemia was similar between LG
and non-LG (P = 0.218).
PPARD +294T/C polymorphism
The frequencies of the minor C-allele were 29.3% and
32.9% in LG and non-LG, respectively, and the genotypes
were distributed according to the Hardy Weinberg
Equilibrium in both groups. Overall, no significant
difference was observed in the frequency distribution
of genotypes and alleles between the two groups (both
P > 0.05). When gender was taken into account, this
distribution pattern remained similar in both sexes in
intragroup comparison, but appeared to lose in females
in intergroup comparison, with C-allele and TC/CC
genotype tending to present more frequently in non-
LG females than that in LG albeit the statistic powers
were less robust (Table 2).
Genotypes and serum lipid levels
In long-lived individuals, while levels of TC, TG, and
HDL-C appeared similar across genotypes, there was a
trend toward higher LDL-C in CC carriers relative to T
carriers (TT/TC), but this tendency was no longer
existed when analyses were stratified by sex. By contrary,
in non-long-lived controls however, LDL-C tended to be
lower in C allele carriers (TC/CC) than did TT carriers.
Similar propensities were also observed on TC and TG
levels in this group, even after sex was analyzed
separately, especially in men. Intergroup comparison
showed that TC, TG, and LDL-C levels of C allele car-
riers (TC and CC) but not TT carriers in LG, regardless
of sex, were significantly higher than that of non-LG,
implying that the minor C but not the wild type T allele
may account in part for the difference of lipid profiles
between LG and non-LG (Table 3).
Correlation between serum lipid parameters and
genotypes
Multiple linear regression analyses showed that in
the combined population, the four lipid parameters
were mainly correlated positively with factors such
as age, sex (female), BMI and diastolic blood pres-
sure. When studied group was considered separately,
LDL-C in LG was also noted to correlate positively
with genotypes while TC, TG, and LDL-C in non-LG
negatively with genotypes besides the above factors
(Table 4). These findings are basically in line with
results in Table 1 and Table 3.
Discussion
In the present study, the long-lived individuals exhib-
ited significant higher TC, TG, and LDL-C levels than
their younger counterparts. Higher mean age of the LG
could not fully explain these differences. Our major
Table 2 Comparison of genotypic and allelic frequency of the PPARD +294T/C polymorphism between LG and non-LG
Subgroup n Genotype n (%) Allele n (%)
TT TC CC T C
LG, all 505 261(51.70) 192(38.00) 52(10.30) 714(70.70) 296(29.30)
Non-LG, all 468 212(45.30) 204(43.60) 52(11.10) 628(67.09) 308(32.91)
χ2 4.039 2.94
P 0.133 0.086
LG, male 127 58(45.70) 56(44.10) 13(10.20) 172(67.70) 82(32.30)
LG, female 378 203(53.70) 136(36.00) 39(10.30) 542(71.70) 214(28.30)
χ2 2.835 1.451
P 0.242 0.228
Non-LG, male 212 100(47.20) 88(41.50) 24(11.30) 288(67.90) 136(32.10)
Non-LG, female 256 112(43.80) 116(45.30) 28(10.90) 340(66.40) 172(33.60)
χ2 0.700 0.242
P 0.705 0.623
LG, male 127 58(45.70) 56(44.10) 13(10.20) 172(67.70) 82(32.30)
Non-LG, male 212 100(47.20) 88(41.50) 24(11.30) 288(67.90) 136(32.10)
χ2 0.249 0.003
P 0.883 0.955
LG, female 378 203(53.70) 136(36.00) 39(10.30) 542(71.70) 214(28.30)
Non-LG, female 256 112(43.80) 116(45.30) 28(10.90) 340(66.40) 172(33.60)
χ2 6.444 4.030
P 0.040 0.045
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morphism of PPARD +294 involves in the modulation
of lipid profile and longevity trait in these cohorts.
One of the important findings herein is the rela-
tively higher frequency of the minor C allele of
the PPARD +294 polymorphism, being 31.04% for
the entire participants investigated, similar to that of
healthy middle-aged Bai Ku Yao (22.50%) and Guangxi
Han Chinese (27.57%) [17], two isolated subpopulations
living in the branches of the upstream of Hongshuihe
River, but noticeably higher than that of healthy
Anhui Han Chinese (19.5%) [24], Korean (22.9%) [9],
Swedish (15.6%) [15], Tunisian (18.9%) [18], Russian
(12.1%) [25], German (19.2%) [19], and French-
Canadians (20.1%) [11], demonstrating a population-
specific allelic distribution pattern worldwide. The
driving forces and the significance of this poly-
morphism in our studying population deserve further
investigation.
The second finding in the current study is the mar-
ginal overrepresentation of minor C allele and geno-
types (TC/CC) in the females of non-LG relative to
that of LG (P = 0.040, 0.045, respectively, Table 2.) and
the inverse relationship between PPARD +294C ratio
and lipid levels in the serum in non-long-lived group.Hitherto, the associations between PPARD +294C and
dyslipidemia, CHD, and other age-related pathologies
have been replicated in several populations. For in-
stance, elevated level of LDL-C was found in CC
enotype carriers as compared to wild type TT homozy-
gotes in Swedish healthy men [15], disease-free
middle-aged Guangxi Han Chinese [17], and German
mild obese and dyslipidemia patients [5]; the C-allele
was significantly more frequent in Tunisian patients
with cardiovascular artery disease than in controls
[18]. Nevertheless, of interest to note is that subjects
homozygous and heterozygous for PPARD +294C
variant in non-LG had lower, instead of higher, levels
of TC, TG and LDL-C. We have no exact explanation
on these controversial results because, according to
published literatures, the transition of nucleotide T to
C at PPARD +294 may relate to either raised or
no-change but not decreased level of unfavorable lipid.
In line with the preponderant view on the disadvanta-
geous role that PPARD +294C may play in lipid modula-
tion, we found a positive correlation between this
polymorphism and lipid levels in long-lived group, which
accounted for the third finding in our study. Thus, it
seems reasonable that the females in LG present less C
allele and CC genotype and this might confer them more
Table 3 Impact of PPARD +294T/C genotype on lipid levels
Subgroup Genotype n TC (mmol/L) TG (mmol/L) HDL-C (mmol/L) LDL-C (mmol/L)
LG, all TT 261 5.05 ± 0.99 0.96(0.49) 1.58 ± 0.39 2.97 ± 0.83
TC 192 5.03 ± 1.01b 0.97(0.49)b 1.60 ± 0.36 2.97 ± 0.90b
CC 52 5.40 ± 1.06b 1.10(0.48)b 1.54 ± 0.35 3.31 ± 0.83ab
TC/CC 244 5.11 ± 1.03b 0.98(0.50)b 1.58 ± 0.36b 3.04 ± 0.89b
LG, male TT 58 4.76 ± 1.04c 0.97(0.48) 1.52 ± 0.41 2.75 ± 0.95c
TC 56 4.73 ± 1.07c 0.89(0.36)c 1.53 ± 0.40 2.77 ± 0.92
CC 13 5.37 ± 1.00d 0.94(0.26) 1.64 ± 0.53 3.30 ± 0.61d
TC/CC 69 4.85 ± 1.08c 0.92(0.33)c 1.55 ± 0.43 2.87 ± 0.89
LG, female TT 203 5.13 ± 0.96 0.96(0.50) 1.60 ± 0.39 3.03 ± 0.78
TC 136 5.15 ± 0.97d 1.02(0.64)d 1.62 ± 0.35 3.05 ± 0.88d
CC 39 5.41 ± 1.09 1.15(0.56) 1.51 ± 0.27d 3.32 ± 0.90
TC/CC 175 5.21 ± 1.00d 1.04(0.63)d 1.59 ± 0.33d 3.11 ± 0.89d
Non-LG, all TT 212 5.04 ± 0.91 0.97(0.55) 1.61 ± 0.38 2.93 ± 0.80
TC 204 4.77 ± 0.93 0.91(0.43) 1.63 ± 0.38 2.71 ± 0.79
CC 52 4.92 ± 0.99a 0.88(0.53)a 1.64 ± 0.32 2.79 ± 0.82a
TC/CC 256 4.80 ± 0.95a 0.89(0.44)a 1.63 ± 0.37 2.72 ± 0.79a
Non-LG, male TT 100 4.96 ± 0.95 0.95(0.75) 1.57 ± 0.37 2.87 ± 0.85
TC 88 4.65 ± 1.05 0.91(0.49) 1.58 ± 0.37 2.63 ± 0.87
CC 24 4.59 ± 0.80c 0.88(0.37)a 1.52 ± 0.24c 2.66 ± 0.72
TC/CC 112 4.64 ± 1.00ac 0.90(0.48)a 1.57 ± 0.35c 2.63 ± 0.84a
Non-LG, female TT 112 5.11 ± 0.88 1.00(0.41) 1.65 ± 0.38 2.99 ± 0.76
TC 116 4.86 ± 0.82 0.91(0.35) 1.66 ± 0.39 2.77 ± 0.72
CC 28 5.21 ± 1.07 0.87(0.61) 1.74 ± 0.35 2.90 ± 0.90
TC/CC 144 4.93 ± 0.88 0.89(0.43)a 1.68 ± 0.38 2.80 ± 0.75a
aP < 0.05 in comparison with TT genotype of the same group; bP < 0.05 in comparison with the same genotype between LG and non-LG; cP < 0.05 intra-group
comparison with the same genotype between sexes; dP < 0.05 intergroup comparison with the same genotype in males or females.
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However, we could not answer the question why the
males in LG who presented similar C allele as general
controls outlived their nineties.
Admittedly, lipid profiles and longevity are much
more complex phenotypes which can not be inter-
preted with sole gene polymorphism. We speculate
that the influence of PPARD + T294C on lipid me-
tabolism, if any, may be limited, as do other lipid
modulating genes such as cholesteryl ester transfer
protein (CETP) [26] and microsomal triglyceride
transfer protein (MTP) gene [20], each of which
exerting small but pleiotropic effect on these com-
plex traits, and this influence may concomitantly be
affected by diet, lifestyle, and the interaction with
other lipid related genes and environment via unrav-
eled pathways.
To sum, our data show that inhabitants residing
in Bama region of Guangxi, China display a higher
minor allele frequency of the PPARD +294T/C poly-
morphism than other populations, with more C alleleand C-containing genotypes representing in younger
controls relative to long-lived individuals. Homozy-
gous CC genotype is associated with increased LDL-C
level in long-lived cohort whereas with decreased TC,
TG and LDL-C levels in non-long-lived counterparts,
demonstrating its age range-specific pattern on lipid
profiles. The lower levels of unfavorable lipids in
the average population in Bama area may relate to
lower morbidity and mortality of age-associated dis-
eases and this may in part pave the way to the
longevity of the region. To the best of our knowledge,
unlike others who mainly focused on younger healthy
or patient populations, our research group is the
first team to explore this polymorphism in long-lived
and general individuals from a unique longevous
region and report a reduced unfavorable lipids as-
sociated with PPARD +294C. However, longitudinal
follow-up studies and gene functional studies are
needed to further elucidate the precise effects of
PPARD +294T/C polymorphism on serum lipids and
longevity in Bama area.











TC DBP 0.012 0.002 0.158 4.905 0.000
Gender 0.306 0.065 0.150 4.679 0.000
TG BMI 0.009 0.002 0.176 5.337 0.000
DBP 0.001 0.000 0.091 2.769 0.006
Age 0.001 0.000 0.075 2.266 0.024
HDL-C BMI −0.012 0.004 −0.111 −3.375 0.001
Gender 0.085 0.026 0.108 3.248 0.001
Age −0.003 0.001 −0.090 −2.688 0.007
LDL-C DBP 0.007 0.002 0.115 3.468 0.001
Gender 0.264 0.065 0.151 4.046 0.000
Age 0.009 0.003 0.129 3.388 0.001
Weight 0.010 0.004 0.114 2.661 0.008
LG
TC DBP 0.013 0.003 0.175 3.900 0.000
Gender 0.344 0.104 0.149 3.318 0.001
TG Weight 0.005 0.001 0.239 4.653 0.000
Gender 0.078 0.019 0.213 4.150 0.000
HDL-C Weight −0.007 0.002 −0.147 −3.204 0.001
DBP 0.002 0.001 0.091 1.981 0.048
LDL-C DBP 0.008 0.003 0.130 2.878 0.004
Gender 0.386 0.105 0.196 3.660 0.000
Genotype 0.136 0.057 0.107 2.384 0.018
Height 0.009 0.004 0.119 2.236 0.026
non-LG
TC Height −0.016 0.005 −0.154 −3.244 0.001
Waist 0.012 0.005 0.115 2.453 0.015
Genotype −0.148 0.064 −0.107 −2.309 0.021
DBP 0.008 0.004 0.102 2.181 0.030
TG BMI 0.022 0.004 0.383 5.601 0.000
Hip −0.006 0.002 −0.209 −3.057 0.002
Genotype −0.034 0.012 −0.130 −2.915 0.004
DBP 0.002 0.001 0.111 2.444 0.015
HDL-C Waist −0.007 0.002 −0.168 −3.685 0.000
Gender 0.108 0.035 0.143 3.118 0.002
Age −0.005 0.002 −0.121 −2.627 0.009
LDL-C Waist 0.019 0.005 0.224 3.651 0.000
SBP 0.004 0.001 0.122 2.657 0.008
Genotype −0.131 0.055 −0.109 −2.371 0.018
Weight −0.011 0.005 −0.127 −2.070 0.039
DBP: Diastolic blood pressure; SBP: Systolic blood pressure; BMI: Body mass index.
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